Standard BioTools Inc. Stock or Unit Option Plan Expense
Standard BioTools Inc. (LAB) reported Stock or Unit Option Plan Expense of $0 for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-11-09.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:StockOptionPlanExpense · last filed 2015-11-09
- Standard BioTools Inc. stock or unit option plan expense for the quarter ending 2015-09-30 was $0.00.
- Standard BioTools Inc. stock or unit option plan expense for the quarter ending 2015-06-30 was $0.00.
- Standard BioTools Inc. stock or unit option plan expense for the quarter ending 2015-03-31 was $0.00, a 100.00% decline year-over-year.
- Standard BioTools Inc. stock or unit option plan expense for the quarter ending 2014-09-30 was $0.00.
| Period end | Stock or Unit Option Plan Expense 3 month | Stock or Unit Option Plan Expense 6 month | Stock or Unit Option Plan Expense 9 month |
|---|---|---|---|
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $0.00 derived: sum of 2 quarters · filed 2015-11-09 | $0.00 10-Q · filed 2015-11-09 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $0.00 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $0.00 10-Q · filed 2015-05-11 | ||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $0.00 derived: sum of 2 quarters · filed 2015-11-09 | $2.65M 10-Q · filed 2015-11-09 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $2.65M 10-Q · filed 2015-08-10 | |
| 2014-03-31 | $2.65M 10-Q · filed 2015-05-11 | ||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $0.00 derived: sum of 2 quarters · filed 2014-11-06 | $0.00 10-Q · filed 2014-11-06 |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04 | $0.00 10-Q · filed 2014-08-04 | |
| 2013-03-31 | $0.00 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |